Fycompa - (2,4,6,8,10,12 mg; Tablet, Oral)

Generic Name	Perampanel	Innovator	EISAI INC
Dosage	2,4,6,8,10,12 mg; Tablet, Oral	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	FYCOMPA, a non-competitive AMPA glutamate receptor antagonist, is indicated as adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
****	*** \ ***	-**-	*** *********	********* ********	** **** **, ****
****** (*****)	*** \ ***	-**-	*** *********	********* ********	** **** **, ****
*** (****)	** \ **	-**-	*** *********	********* ********	***** ***-**** ***********

Chronology Of Events

Fycompa - (0.5 mg/mL ; Oral Suspension)

Generic Name	Perampanel	Innovator	EISAI INC
Dosage	0.5 mg/mL ; Oral Suspension	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	FYCOMPA, a non-competitive AMPA glutamate receptor antagonist, is indicated as adjunctive therapy for the treatment of: 1)Partial-Onset Seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older 2)Primary Generalized Tonic-Clonic Seizures in patients with epilepsy 12 years of age and older
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*** ****	*** \ *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events